Published in J Hepatol on May 01, 2004
The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings. Ann Intern Med (2011) 3.80
Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. Ann Intern Med (2015) 2.07
Incidence and predictors of 30-day readmission among patients hospitalized for advanced liver disease. Clin Gastroenterol Hepatol (2010) 1.48
Gut flora and bacterial translocation in chronic liver disease. World J Gastroenterol (2006) 1.29
What are the implications of the spontaneous spleno-renal shunts in liver cirrhosis? BMC Gastroenterol (2009) 1.24
Blood ammonia levels in liver cirrhosis: a clue for the presence of portosystemic collateral veins. BMC Gastroenterol (2009) 1.19
Hepatitis C, stigma and cure. World J Gastroenterol (2013) 1.13
Clinical relevance of sarcopenia in patients with cirrhosis. World J Gastroenterol (2014) 1.03
Cost-effectiveness of boceprevir in patients previously treated for chronic hepatitis C genotype 1 infection in the United States. Value Health (2013) 1.01
Risk factors for frequent readmissions and barriers to transplantation in patients with cirrhosis. PLoS One (2013) 0.98
Proton beam therapy for hepatocellular carcinoma patients with severe cirrhosis. Strahlenther Onkol (2006) 0.96
Hepatitis C Disease Burden in the United States in the era of oral direct-acting antivirals. Hepatology (2016) 0.95
Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study. BMC Infect Dis (2013) 0.93
Clinical Monitoring of Chronic Hepatitis C Based on its Natural History and Therapy. N Am J Med Sci (Boston) (2014) 0.88
The incidence of hepatocellular carcinoma associated with hepatitis C infection decreased in Kyushu area. Med Sci Monit (2011) 0.86
Improving survival in decompensated cirrhosis. Int J Hepatol (2012) 0.86
Management of treatment-naïve chronic hepatitis C genotype 1 patients: a cost-effectiveness analysis of treatment options. J Viral Hepat (2014) 0.85
A cost-utility analysis of drug treatments in patients with HBeAg-positive chronic hepatitis B in Thailand. BMC Health Serv Res (2014) 0.85
Bacteremia and "Endotipsitis" following transjugular intrahepatic portosystemic shunting. World J Hepatol (2011) 0.84
A record-linkage study of the development of hepatocellular carcinoma in persons with hepatitis C infection in Scotland. Br J Cancer (2008) 0.84
Advanced disease, diuretic use, and marital status predict hospital admissions in an ambulatory cirrhosis cohort. Dig Dis Sci (2013) 0.83
Outcome prediction of diffuse large B-cell lymphomas associated with hepatitis C virus infection: a study on behalf of the Fondazione Italiana Linfomi. Haematologica (2013) 0.82
Hepatitis C in human immunodeficiency virus co-infected individuals: Is this still a "special population"? World J Hepatol (2015) 0.81
Incisional hernia as an unusual cause of hepatic encephalopathy in a 62-year-old man with cirrhosis: a case report. J Med Case Rep (2009) 0.81
Activation of inactive hepatocytes through histone acetylation: a mechanism for functional compensation after massive loss of hepatocytes. Am J Pathol (2011) 0.80
SASLT practice guidelines: management of hepatitis C virus infection. Saudi J Gastroenterol (2012) 0.80
Economic and Public Health Impacts of Policies Restricting Access to Hepatitis C Treatment for Medicaid Patients. Value Health (2016) 0.80
Cost-effectiveness of new antiviral regimens for treatment-naïve U.S. veterans with hepatitis C. Hepatology (2015) 0.79
Use of the Model for End-Stage Liver Disease (MELD) score to predict 1-year survival of Japanese patients with cirrhosis and to determine who will benefit from living donor liver transplantation. J Gastroenterol (2008) 0.78
Chronic Hepatitis C: An Overview of Evidence on Epidemiology and Management from a Brazilian Perspective. Int J Hepatol (2015) 0.78
Thyroid disease in chronic hepatitis C infection treated with combination interferon-α and ribavirin: management strategies and future perspective. Endocr Pract (2013) 0.77
Role of systemic inflammation in cirrhosis: From pathogenesis to prognosis. World J Hepatol (2015) 0.77
Direct antiviral agent treatment of decompensated hepatitis C virus-induced liver cirrhosis. World J Gastrointest Pharmacol Ther (2015) 0.76
AST to Platelet Ratio Index Predicts Mortality in Hospitalized Patients With Hepatitis B-Related Decompensated Cirrhosis. Medicine (Baltimore) (2016) 0.76
Economic evaluation of pegylated interferon plus ribavirin for treatment of chronic hepatitis C in Thailand: genotype 1 and 6. BMC Gastroenterol (2016) 0.75
Estimating cost-effectiveness associated with all-oral regimen for chronic hepatitis C in China. PLoS One (2017) 0.75
Continuous furosemide infusion in the management of ascites. J Investig Med (2012) 0.75
Reversed portal flow: Clinical influence on the long-term outcomes in cirrhosis. World J Gastroenterol (2015) 0.75
Cost Effectiveness of Daclatasvir/Asunaprevir Versus Peginterferon/Ribavirin and Protease Inhibitors for the Treatment of Hepatitis c Genotype 1b Naïve Patients in Chile. PLoS One (2015) 0.75
Significant Morbidity and Mortality Among Hospitalized End-Stage Liver Disease Patients in Medicare. J Pain Symptom Manage (2016) 0.75
Changing Cycle Lengths in State-Transition Models: Challenges and Solutions. Med Decis Making (2016) 0.75
Proportions of acetyl-histone-positive hepatocytes indicate the functional status and prognosis of cirrhotic patients. World J Gastroenterol (2015) 0.75
Outcomes after sofosbuvir-containing regimens for hepatitis C virus in patients with decompensated cirrhosis: a real-world study. Infect Agent Cancer (2017) 0.75
Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet (2002) 12.16
Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin. Hepatology (2009) 3.28
Hospital admission is a relevant source of hepatitis C virus acquisition in Spain. J Hepatol (2007) 3.21
Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology (2007) 3.19
Serum and ascitic fluid bacterial DNA: a new independent prognostic factor in noninfected patients with cirrhosis. Hepatology (2008) 1.96
Exocrine pancreatic cancer: symptoms at presentation and their relation to tumour site and stage. Clin Transl Oncol (2005) 1.44
Natural history of patients hospitalized for management of cirrhotic ascites. Clin Gastroenterol Hepatol (2006) 1.30
Serotonin and interleukin-6: the role of genetic polymorphisms in IFN-induced neuropsychiatric symptoms. Psychoneuroendocrinology (2013) 1.29
Interferon-induced depression in chronic hepatitis C: a systematic review and meta-analysis. J Clin Psychiatry (2012) 1.28
Cerebral venous congestion as indication for thrombolytic treatment. Cardiovasc Intervent Radiol (2007) 1.03
Mechanisms of early decrease in systemic vascular resistance after total paracentesis: influence of flow rate of ascites extraction. Eur J Gastroenterol Hepatol (2004) 1.02
Spironolactone alone or in combination with furosemide in the treatment of moderate ascites in nonazotemic cirrhosis. A randomized comparative study of efficacy and safety. J Hepatol (2003) 0.96
Efficacy and safety of entecavir in clinical practice in treatment-naive Caucasian chronic hepatitis B patients. Eur J Gastroenterol Hepatol (2012) 0.96
Advanced liver fibrosis in HIV/HCV-coinfected patients on antiretroviral therapy. AIDS Res Hum Retroviruses (2004) 0.96
Pulling geometry-induced errors in single molecule force spectroscopy measurements. Biophys J (2007) 0.95
Probability of liver cancer and survival in HCV-related or alcoholic-decompensated cirrhosis. A study of 377 patients. Liver Int (2006) 0.94
Paracetamol in therapeutic dosages and acute liver injury: causality assessment in a prospective case series. BMC Gastroenterol (2011) 0.93
Prophylactic treatment with escitalopram of pegylated interferon alfa-2a-induced depression in hepatitis C: a 12-week, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry (2010) 0.88
Long-term clinical course of decompensated alcoholic cirrhosis: a prospective study of 165 patients. J Clin Gastroenterol (2011) 0.88
Serum concentrations of insulin-like growth factor-I (igf-I) as a marker of liver fibrosis in patients with chronic hepatitis C. Dig Dis Sci (2007) 0.86
Poor response to hepatitis C virus (HCV) therapy in HIV- and HCV-coinfected patients is not due to lower adherence to treatment. AIDS Res Hum Retroviruses (2006) 0.85
Incidence and prognosis of different types of functional renal failure in cirrhotic patients with ascites. Clin Gastroenterol Hepatol (2010) 0.85
Pegylated interferon and ribavirin-induced depression in chronic hepatitis C: role of personality. J Clin Psychiatry (2009) 0.85
Enterococcus gallinarum bacteriascites in a patient with active tuberculosis and HCV cirrhosis. Am J Gastroenterol (2002) 0.84
The role of locomotion in psychological development. Front Psychol (2013) 0.84
A randomized trial of basiliximab with three different patterns of cyclosporin A initiation in renal transplant from expanded criteria donors and at high risk of delayed graft function. Clin Transplant (2008) 0.83
Prophylactic antidepressant treatment of interferon-induced depression in chronic hepatitis C: a systematic review and meta-analysis. J Clin Psychiatry (2014) 0.83
Differences in virological response to pegylated interferon and ribavirin between hepatitis C virus (HCV)-monoinfected and HCV-HIV-coinfected patients. Antivir Ther (2008) 0.83
Carbon nanotube-nanocup hybrid structures for high power supercapacitor applications. Nano Lett (2012) 0.80
Time and distance dependence of reversible polymer bridging followed by single-molecule force spectroscopy. Langmuir (2008) 0.80
Ability of treatment week 12 viral response to predict long-term outcome in genotype 1 hepatitis C virus/HIV coinfected patients. AIDS (2010) 0.80
Relationships of hepatic and pancreatic biomarkers with the cholestatic syndrome and tumor stage in pancreatic cancer. Biomarkers (2012) 0.79
Drug-drug interactions of telaprevir and boceprevir in HCV-monoinfected and HIV/HCV-coinfected patients can modify the adherence. Liver Int (2014) 0.79
A multidisciplinary support programme increases the efficiency of pegylated interferon alfa-2a and ribavirin in hepatitis C. J Hepatol (2013) 0.78
[Prevalence of hepatitis B and hepatitis C viruses in different counties of Catalonia, Spain: cross-sectional study]. Med Clin (Barc) (2002) 0.78
Successful liver and kidney transplantation from cadaveric donors with left-sided bacterial endocarditis. Am J Transplant (2005) 0.78
Short communication. Baseline factors associated with haematological toxicity that leads to a dosage reduction of pegylated interferon-alpha2a and ribavirin in HIV- and HCV-coinfected patients on HCV antiviral therapy. Antivir Ther (2005) 0.77
Effect of compressive force on unbinding specific protein-ligand complexes with force spectroscopy. J Phys Chem B (2013) 0.77
Combining steroids with enteral nutrition: a better therapeutic strategy for severe alcoholic hepatitis? Results of a pilot study. Eur J Gastroenterol Hepatol (2004) 0.77
Depression as Measured by PHQ-9 Versus Clinical Diagnosis as an Independent Predictor of Long-Term Mortality in a Prospective Cohort of Medical Inpatients. Psychosom Med (2017) 0.76
[Position paper of the Catalan Society of Gastroenterology: treatment of Genotype 1 Chronic Hepatitis C Virus with Triple Therapy]. Gastroenterol Hepatol (2012) 0.76
Evolutionary dynamics of the E1-E2 viral populations during combination therapy in non-responder patients chronically infected with hepatitis C virus subtype 1b. Infect Genet Evol (2012) 0.76
Single-Molecule Force Spectroscopy of DNA-Based Reversible Polymer Bridges: Surface Robustness and Homogeneity. Colloids Surf A Physicochem Eng Asp (2009) 0.75
Do Physical Therapy Interventions Affect Urinary Incontinence and Quality of Life in People with Multiple Sclerosis?: An Evidence-Based Review. Int J MS Care (2015) 0.75
Profiles and clinical management of hepatitis C patients in Spain: disHCovery study. Rev Esp Quimioter (2015) 0.75
Peginterferon- and ribavirin-induced bipolar episode successfully treated with lamotrigine without discontinuation of antiviral therapy. Gen Hosp Psychiatry (2008) 0.75
Pharmacoeconomic analysis of the treatment of chronic hepatitis C with peginterferon alfa-2a or peginterferon alfa-2b plus ribavirin in Spain. Gastroenterol Hepatol (2013) 0.75
Stereoselective aminoxylation of biradical titanium enolates with TEMPO. Chemistry (2014) 0.75
[Hepatic elastography. Position paper of the Catalan Society of Gastroenterology]. Gastroenterol Hepatol (2011) 0.75
[Cost of screening for hepatocarcinoma in patients with cirrhosis: a prospective study]. Gastroenterol Hepatol (2011) 0.75
Entecavir has high efficacy and safety in white patients with chronic hepatitis B and comorbidities. Eur J Gastroenterol Hepatol (2015) 0.75
Update on brow and forehead lifting. Curr Opin Otolaryngol Head Neck Surg (2006) 0.75
Effect of an induction period of pegylated interferon-α2a and ribavirin on early virological response in HIV-HCV-coinfected patients: results from the CORAL-2 study. Antivir Ther (2011) 0.75
[Prevalence of potential interactions between antiretroviral therapy and boceprevir or telaprevir in human immunodeficiency virus-hepatitis C virus coinfected patients]. Enferm Infecc Microbiol Clin (2012) 0.75
Stereoselective titanium-mediated aldol reactions of a chiral lactate-derived ethyl ketone with ketones. Org Lett (2013) 0.75